We stand at the crossroads of medical innovation, where cutting-edge scientific discoveries intersect with the resilience of the human body, providing hope to families grappling with a diagnosis of pediatric leukemia. In an editorial paper, published in Oncoscience...
SHANGHAI, NANJING, China, and SAN JOSE, Calif., May 10, 2024 /PRNewswire/ — On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled “Single-cell analysis of anti-BCMA...
Agreement allows ImmunoACT to develop and commercialize a novel TriCAR-T cell therapy for leukemia and lymphoma designed to decrease lapses seen in current single CAR-T cell therapies and improve outcomes GAITHERSBURG, Md. and MUMBAI, India, May 7, 2024 /PRNewswire/...
Astellas Pharma, through its subsidiary Xyphos Biosciences, has entered into a second collaborative agreement with Poseida Therapeutics to pioneer the development of off-the-shelf cell therapies for solid tumors. This follows their initial partnership in 2023, which...
Cellares has inked its first international deal with Bristol Myers Squibb, with the cell therapy manufacturer noting it is going through “tremendous tailwinds” from the Biosecure Act with increased interest from many potential clients. Bristol Myers has reserved...
